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Encephalocraniocutaneous lipomatosis (ECCL) is a sporadic condition characterized by ocular, cutaneous, and central nervous system
anomalies. Key clinical features include a well-demarcated hairless fatty nevus on the scalp, benign ocular tumors, and central nervous
system lipomas. Seizures, spasticity, and intellectual disability can be present, although affected individuals without seizures and with
normal intellect have also been reported. Given the patchy and asymmetric nature of the malformations, ECCL has been hypothesized
to be due to a post-zygotic, mosaic mutation. Despite phenotypic overlap with several other disorders associated with mutations in
the RAS-MAPK and PI3K-AKT pathways, the molecular etiology of ECCL remains unknown. Using exome sequencing of DNA from
multiple affected tissues from five unrelated individuals with ECCL, we identified two mosaic mutations, c.1638C>A (p.Asn546Lys)
and c.1966A>G (p.Lys656Glu) within the tyrosine kinase domain of FGFR1, in two affected individuals each. These two residues are
the most commonly mutated residues in FGFR1 in human cancers and are associated primarily with CNS tumors. Targeted resequencing
of FGFR1 in multiple tissues from an independent cohort of individuals with ECCL identified one additional individual with a
c.1638C>A (p.Asn546Lys) mutation in FGFR1. Functional studies of ECCL fibroblast cell lines show increased levels of phosphorylated
FGFRs and phosphorylated FRS2, a direct substrate of FGFR1, as well as constitutive activation of RAS-MAPK signaling. In addition to
identifying the molecular etiology of ECCL, our results support the emerging overlap between mosaic developmental disorders and
tumorigenesis.Congenital malformations featuring asymmetry, focal
anomalies, or segmental overgrowth have long been hy-
pothesized to be due to post-zygotic (mosaic) mutations.1
Gene discovery for these disorders has been challenging
due to the absence of familial recurrence, difficulty obtain-
ing affected tissues, and the challenge of detecting low-
frequency genetic variation. Encephalocraniocutaneous
lipomatosis (ECCL; [MIM 613001]) is a sporadic neurocuta-
neous disorder characterized by patchy, asymmetric mal-
formations and absence of familial recurrence.2 Given
this presentation, as well as an equal sex ratio and the
occurrence of discordant monozygotic twins, ECCL has
been hypothesized to be due to mosaic mutations.3–5
ECCL is characterized by cutaneous, ocular, and central
nervous system (CNS) abnormalities, and in the absence
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The Amepresence of characteristic clinical features.2,6 The most
characteristic skin anomaly in ECCL is nevus psiloliparus,
a well-demarcated, alopecic fatty tissue nevus on the scalp
seen in 80% of affected individuals.2 Other dermatologic
features include frontotemporal or zygomatic subcutane-
ous fatty lipomas, non-scarring alopecia, focal dermal
hypoplasia or aplasia of the scalp, periocular skin tags,
and pigmentary abnormalities following the lines of
Blaschko. Choristomas of the eye (epibulbar dermoids or
lipodermoids) are also frequent (80% of individuals with
ECCL), and can be unilateral or bilateral.2 Characteristic
CNS features in ECCL include intracranial and intraspinal
lipomas (61% of affected individuals), and less often cere-
bral asymmetry, arachnoid cysts, enlarged ventricles, and
leptomeningeal angiomatosis.7 A predisposition to low-
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Table 1. Clinical Features of 5 Individuals with ECCL in Whom an FGFR1 Mutation Was Detected
LR12-068 LR13-278 IN_0039 NIH_183 LR14-261
FGFR1 mutation c.1966A>G
(p.Lys656Glu)
c.1638C>A
(p.Asn546Lys)
c.1638C>A
(p.Asn546Lys)
c.1966A>G
(p.Lys656Glu)
c.1638C>A
(p.Asn546Lys)
Mutation discovery
method
ES ES ES ES smMIP
Age at last assessment 7 y 15 y 17 m 2 y 8m 5 y
Gender M M M M F
Neurocognitive
function
normal delayed, in special
skills class
normal normal normal
Seizures no yes no no no
Intracranial lipomas yes yes yes no yes
Spinal lipomas no not assessed yes (T2/3 and L5/S1) no no
CNS Other Pilomyxoid/ pilocytic
astrocytoma
WHO I
Tectal tumor, left
temporal cortical
dysplasia
no Pilocytic/ pilomyxoid
astrocytoma
WHO II
no
Nevus psiloliparus yes yes yes yes yes
Alopecia yes yes yes yes (right parietal) yes
Subcutaneous lipoma yes (fronto-temporal) yes yes (fronto-temporal) yes (parietal) yes
Focal scalp aplasia yes yes yes yes no
Skin tags yes (eyelid) yes yes yes (right eyelid,
anterior to right ear)
yes
Choristoma yes (bilateral) yes yes (right) no yes
Coloboma no yes (left upper eyelid) yes (left upper eyelid,
iris and bilateral retinal)
no (but segmental iris
heterochromia present)
no
Prior Publication no yes59 no yes8 yes60
Abbreviations are as follows: ES (exome sequencing) and mMIP (single molecule molecular inversion probes).intellectual disability are common but normal intellect is
seen in a third of affected individuals.2 Skeletal manifesta-
tions include bone cysts and jaw tumors, such as odonto-
mas, osteomas, and ossifying fibromas.13 ECCL had been
proposed to be a localized form of Proteus syndrome
(MIM 176920), although diagnostic criteria suggest that
the two conditions are clinically distinct.2
To identify the molecular etiology of ECCL, we per-
formed exome sequencing (ES) on DNA samples from
five unrelated ECCL probands (IN_0039, LR12-068, LR13-
278, LR13-175, NIH_183). Written informed consent to
participate in this study was obtained for each participant.
This study was approved by ethics review boards at the
Children’s Hospital of Eastern Ontario, Seattle Children’s
Hospital, and the National Human Genome Research
Institute. Clinical features of these affected individuals
are described in Table 1 and highlighted in Figures 1A–
1D. To maximize the likelihood of detecting low fre-
quency, tissue-restricted mosaic variants, we sequenced
DNA at high coverage (64-172X) from probands’ affected
and unaffected tissue where possible. ES was also per-
formed on blood-derived DNA from parents of probands
LR12-068, LR13-278, LR13-175, NIH_183, and from the
unaffected monozygotic twin sibling of IN_0039. ES plat-
forms and data analyses are detailed in Tables S1 and S2.580 The American Journal of Human Genetics 98, 579–587, March 3Genomic alterations identified by ES were screened against
variants in the NHLBI Exome Sequencing Project Exome
Variant Server (EVS), the Exome Aggregation Consortium
(ExAC), the NCBI database (dbSNP), and in-house variant
databases. Variants inherited from a parent, or present in
the unaffected twin in the case of IN_0039, were also
filtered out.
Two rare missense variants, c.1638C>A (p.Asn546Lys)
and c.1966A>G (p.Lys656Glu), located within the
intracellular tyrosine kinase domain of FGFR1 (NM_
023110.2), were identified in four of the five probands
(Figures 1E and 1F). In IN_0039, the affected proband of
a monozygotic twin pair discordant for ECCL, the
p.Asn546Lys substitution was identified in fibroblasts
cultured from biopsies of both unaffected skin (23% alter-
nate allele fraction, AAF) and a scalp lesion (33% AAF), but
was absent (0/76 reads at this position) from the unaffected
twin’s blood. In individual LR13-278, the p.Asn546Lys
substitution was identified in fibroblasts cultured from
biopsies of unaffected skin (35% AAF), scalp nevus (42%
AAF), and eyelid dermoid (54% AAF). In proband
NIH_183, the p.Lys656Glu substitution was identified in
fibroblasts cultured from a scalp lesion (45% AAF) but
was not detected in blood. In proband LR12-068, the
p.Lys656Glu substitution was identified in fibroblasts, 2016
Figure 1. Exome Sequencing Identifies FGFR1 Mutations in Four Individuals with ECCL
(A) Photograph of LR13-278, showing nevus psiloliparus (asterisk) and subcutaneous lipoma (arrow).
(B) Horizontal T2 MRI of LR12-068, showing pilocytic astrocytoma (light blue arrow) adjacent to posterior left lateral ventricle.
(C) Photograph of IN_0039, showing large subcutaneous lipoma (asterisk), epibulbar dermoid (arrow), and eyelid skin tag (arrowhead).
(D) Photograph of NIH_183 showing several regions of focal skin hypoplasia over vertex (arrow) and nevus psiloliparus anteriorly
(asterisk).
(E) Protein structure of FGFR1. The three extracellular Ig-like domains, the transmembrane (TM) domain, and the two-part tyrosine ki-
nase (TK1 and TK2) domain are shown. Locations of mutations for two other syndromes due to activating FGFR1 substitutions are
shown: Pfeiffer syndrome in green (p.Pro252Arg) and osteoglophonic dysplasia in yellow (p.Asn330Ile, p.Tyr374Cys, and p.Cys381Arg).
The two ECCL associated substitutions (p.Asn546Lys and p.Lys656Glu) are located in the cytoplasmic kinase domain.
(F) Amino acid sequences of FGFR1, 2, and 3 (P11362.3, P22607.1, P21802.1) were aligned usingMUSCLE Alignment with the Geneious
software.55 In addition to the two ECCL substitutions in FGFR1, disorders associated with substitutions in paralogous amino acids in
FGFR241,56 and FGFR326,34,57,58 are also shown. Abbreviations: CRS (craniosynostosis), HCH (hypochondroplasia), TD (thanatophoric
dysplasia), and SADDAN (Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans)cultured from a scalp nevus (47% AAF), and from a pilo-
cytic astrocytoma (32% AAF). In each case the FGFR1
variant detected by exome sequencing was confirmed by
Sanger sequencing. Neither of these two variants was pre-
sent in EVS, ExAC, or dbSNP. No rare non-synonymous
variants were identified in FGFR1 in LR13-175. Coverage
information for all eleven exome samples is included in Ta-
ble S1. On the basis of finding four unrelated individuals
with the same rare phenotype who shared one of two
missense mutations in the same gene, we considered these
variants in FGFR1 to be pathogenic and causative of ECCL.
ES identified an additional FGFR1 variant, c.1681G>A
(p.Val561Met), in LR12-068, in 45/87 reads (45% AAF).
This variant was present in the pilocytic astrocytoma but
not in cultured skin fibroblasts (0/183 reads). Interestingly,
this variant has been reported to confer resistance to
lucitanib, a tyrosine kinase inhibitor (TKI) currently in
phase II trials for FGFR-dependent tumors.14,15 However,
to mediate TKI resistance, the c.1681G>A (p.Val561Met)
variant must be in cis with the primary FGFR1 activating
mutation.14 We hypothesized that p.Val561Met was a
second hit that arose during tumorigenesis in cis with
this individual’s primary FGFR1 mutation, c.1966A>GThe Ame(p.Lys656Glu). To test this, we subcloned DNA from the
tumor sample. Briefly, a 1,408 basepair fragment contain-
ing both c.1681G>A and c.1966A>G was amplified from
tumor DNA (primers listed in Table S3), subcloned into a
plasmid (pCR2.1-TOPO, Life Technologies) using TOPO-
TA cloning, and used to transform competent cells. Col-
onies containing the fragment were identified by PCR,
expanded in liquid culture, and genotyped by Sanger
sequencing. Of 20 clones isolated, 16 possessed neither
variant, two possessed only the p.Lys656Glu variant, and
two possessed both variants. These results suggest that
the c.1681G>A (p.Val561Met) variant is in cis with the
c.1966A>G (p.Lys656Glu) mutation, and possibly arose
during tumorigenesis.
To facilitate the identification of mutations in FGFR1
in additional individuals suspected of having ECCL, we
developed an approach using single molecule Molecular
Inversion Probes (smMIPs) because low-frequency mosaic
mutations could be missed using conventional Sanger
sequencing. smMIPs are an inexpensive and highly sensi-
tive next generation sequencing method that have been
reported to detect alleles present as low as 0.1%,16 lower
than the typical Sanger cutoff of 20%. smMIPs allowsrican Journal of Human Genetics 98, 579–587, March 3, 2016 581
independent molecular capture events to be distinguished,
so that smMIP coverage is reported as independent reads,
each of which represents an individual capture event.16
Briefly, smMIPs were designed to capture all coding regions
of FGFR1 plus at least ten bases of flanking sequence. A
pool of 47 smMIPs (sequences in Table S4) was hybridized
with 120 ng of DNA from each sample in the cohort. Each
smMIP contained a 5 nucleotide degenerate ‘‘molecular
tag’’ used to distinguish independent molecular capture
events. Sample-specific eight-base barcodes were intro-
duced in subsequent PCR amplification steps, and pooled
libraries were sequenced using a 101 cycle paired end
protocol on an Illumina MiSeq. Reads were aligned to the
human assembly hg19 using BWA, and GATK was used
to refine local alignments and call variants (SNVs and
indels). Reads with the same molecular barcode were
collapsed to form independent reads, and we required
the presence of a variant in three or more independent
reads. We used smMIPs to screen multiple tissues from
two probands (LR13-278 and IN_0039, see Table S5) with
mutations in FGFR1 detected by ES to determine the
tissue distribution of the mutations. In LR13-278, the
c.1638C>A (p.Asn546Lys) mutation was detected in
DNA derived from fibroblasts (affected and unaffected
skin), but was absent in blood- or saliva-derived DNA at a
depth of 153 and 27 independent reads, respectively.
This same mutation was detected in DNA derived from fi-
broblasts (affected skin) from individual IN_0039, but
was absent in saliva, buccal swab, and blood-derived
DNA, at depths of 114, 40, and 51 independent reads,
respectively. At a depth of 27 independent reads, the
smMIPs assay should be able to detect variants at a fre-
quency as low as 11% (3/27). At a depth of 153 indepen-
dent reads, the detection limit is as low as 2% (3/153).
Because we were unable to detect FGFR1 mutations in
blood, saliva, or buccal swab derived DNA in two individ-
uals with known mutations present at high levels (31%–
55% AAF, see Table S5) in biopsied tissues, we suspect
that the tissue distribution of FGFR1mutations in individ-
uals with ECCL is skewed. Although it is possible that the
FGFR1 mutations are present in blood, saliva, or buccal
swab at levels below our detection limit, these results
suggest that the negative predictive value of FGFR1
sequencing of these non-biopsied samples might be low
for ECCL and that sequencing of skin-biopsy derived
DNA will provide a higher diagnostic yield.
Using the same smMIP assay, we screened an indepen-
dent cohort of four individuals with ECCL (LR14-261,
LR04-090, LR09-120, and IN_0025, see Table S5) for
whom tissue biopsy-derived DNA was available. We iden-
tified one additional individual (LR14-261) with the
c.1636C>A (p.Asn546Lys) mutation in FGFR1, present at
an allele fraction of 55% (110 of 199 independent reads)
in DNA isolated from cultured fibroblasts from a scalp
nevus, but was not detected in saliva (0/36 independent
reads, see Table S5). Clinical details about this individual
are listed in Table 1. No other FGFR1mutations were iden-582 The American Journal of Human Genetics 98, 579–587, March 3tified within any samples from these four individuals in
which tissue biopsy-derived DNA was available. An addi-
tional group of three individuals (LR04-093, LR09-252,
and LR14-210) with ECCL were screened using the smMIP
assay, but for these three individuals only blood or saliva
derived DNA was available (see Table S5). No additional
FGFR1 mutations were detected in this group, but since
we did not have tissue biopsy-derived DNA available in
this group, FGFR1 mutations cannot be excluded. Clinical
phenotypes of the individuals in which an FGFR1 muta-
tion was not detected were not different from those of in-
dividuals with an FGFR1 mutation (data not shown). The
number of independent reads at each of the two FGFR1
mutation sites, for each tissue tested, is shown in Table S5.
Receptor tyrosine kinases (RTKs) regulate a wide range
of complex biological functions including cell growth,
differentiation, tissue patterning, and organogenesis.17,18
Fibroblast growth factor receptors (FGFRs) represent an
RTK subfamily comprising four homologous receptors
encoded by four FGFR genes. The encoded proteins share
a basic structure consisting of three extracellular ligand-
binding immunoglobulin domains (IgI, IgII, IgIII) linked
to a cytoplasmic protein kinase core (TK1 and TK2) via a
single-pass transmembrane domain (TM) (Figures 1E and
2A).19 The two recurrent FGFR1 substitutions are located
within the cytoplasmic kinase core (Figures 1E and 1F).
FGFRs function by binding their respective ligands and
heparan accessory molecules to induce dimerization and
conformational changes.17,20 Following ligand binding,
trans-phosphorylation of the cytoplasmic domains be-
tween dimer pairs releases cis-autoinhibition and enables
catalytic kinase activity.20–22 Phosphorylation of additional
tyrosine sites in the kinase domain creates high affinity
binding sites for proteins containing phosphotyrosine
binding (PTB) domains and Src-homology 2 domains.21
Catalytically active receptors initiate intracellular signaling
through several pathways, including the RAS-MAPK
network (Figure 2A), resulting in phosphorylation of down-
stream targets such as ERK1, ERK2, and C-RAF (HUGO gene
names are MAPK3, MAPK1, and RAF1, respectively).
To determine the effect of ECCL mutations on FGFR
activity, we conducted Western blot analysis of whole
cell extracts from several fibroblast lines derived from
LR13-278, who harbors the p.Asn546Lys substitution.
Using antibodies that detect phosphorylation of FGFR1-4
on Tyr653 and Tyr654 (pFGFR-Y653/Y654), we observed
spontaneously elevated levels of phosphorylated FGFRs
in exponentially growing fibroblasts derived from the
skin, eyelid, and scalp of LR13-278, compared to wild-
type (WT) cells (Figure 2B). We next examined signal
transduction in these cells following prolonged serum
deprivation, compared to exponentially growing cells.
WT fibroblasts showed the expected reduction in phos-
phorylation of FGFR (Figure 2C) and ERK1/2 phos-
phorylation (pERK1/2-T202/Y204) upon serum starvation
(Figure 2C). In contrast, fibroblasts from LR13-278 ex-
hibited elevated phosphorylation of FGFR and ERK1/2, 2016
Figure 2. Hyperphosphorylation of FGFR and RAS-MAPK Activation in an Individual with ECCL Due to p.Asn546Lys Substitution
(A) Ligand and heparan-sulfate binding induces FGFR dimerization and conformational changes followed by trans-phosphorylation and
activation of the cytoplasmic kinase domain. Phosphorylation of additional tyrosine sites in the kinase domain creates high affinity
binding sites for downstream effector proteins such as FRS2, which recruits GRB2 and initiates RAS-MAPK signaling. The three extracel-
lular Ig-like domains, the acid box (AB), heparan-sulfate (HS), heparan-sulfate binding site (HSB), fibroblast growth factor (FGF), and the
two-part tyrosine kinase (TK1 and TK2) domain are shown.
(B) Differing amounts of whole-cell extract (WCE) from exponentially growing wild-type (WT) and ECCL fibroblasts derived from
various tissues from LR13-278 were probed for FGFR-phosphorylation using pan-FGFR phosphorylation antibodies (pFGFR-Tyr653/
Tyr654).
(C) WCE was prepared from exponentially growing cells (þ serum) and from cells that were serum starved for 72 hr ( serum) from
wild-type (WT) fibroblasts and from various tissues from LR13-278. These were blotted using antibodies to detect pan-FGFR transphos-
phorylation and ERK1/2 phosphorylation.
(D) All fibroblasts were serum starved for 72 hr and then either untreated () or treated (þ) with bFGF (10 nM for 15 min). WCE from
wild-type (WT) and LR13-278 fibroblasts from various tissues were blotted to detect ERK1/2 and C-RAF phosphorylation and also for
FRS2 phosphorylation. All antibodies were obtained from Cell Signaling Technology: anti-pFGFR-Tyr653/Tyr654 (Cat #3471S), anti-
FGFR-1 (Cat #9740), anti-pFRS2-Tyr463 (Cat #3861S), anti-pERK1/2-Thr202/Tyr204 (Cat #9101S), anti-ERK1/2 (Cat #4695S), and
anti-pC-RAF-Ser259 (Cat #9421).compared to WT in the presence or absence of serum
(Figure 2C). Similar results were observed in fibroblasts
derived from the thigh and scalp of IN_0039 (data not
shown). Finally, we examined FGFR-dependent signal
transduction in LR13-278 fibroblasts in response to acute
treatment with recombinant basic fibroblast growth factor
(bFGF) following prolonged serum deprivation. WT fibro-
blasts treated with bFGF showed elevated levels of phos-
phorylated ERK1/2 and C-RAF, another RAS-pathway
effector (Figure 2D). In contrast, fibroblasts from LR13-
278 showed elevated levels of phosphorylated ERK1/2The Ameand C-RAF even in the absence of bFGF stimulation
(Figure 2D), suggesting ligand-independent activation
of FGFR signaling. Because phosphorylated ERK1/2 and
C-RAF can reflect increased activity of a variety of RTKs,
we also examined FRS2, whose activating phosphorylation
is mainly FGFR-dependent.23 Similar to ERK1/2 and C-RAF,
phosphorylated FRS2 is increased by bFGF stimulation
in WT fibroblasts, but in LR13-278 elevated levels of
phosphorylated FRS2 are present even in the absence of
bFGF stimulation (Figure 2D). Collectively, these results
demonstrate elevated autophosphorylation of FGFRs, therican Journal of Human Genetics 98, 579–587, March 3, 2016 583
FGFR-dependent substrate FRS2, and the RAS-pathway
components C-RAF and ERK1/2, in multiple proband-
derived fibroblasts with the p.Asn546Lys substitution
(Figures 2B–2D and data not shown). A proband-derived
fibroblast line harboring the p.Lys656Glu substitution
was unavailable for this study.
We have shown that mosaic, activating substitutions
at two residues (p.Asn546Lys and p.Lys656Glu) in the
cytoplasmic tyrosine kinase domain of FGFR1 cause
ECCL. The involvement of FGFRs in human disease is
well documented.24,25 Germline gain-of-function muta-
tions in FGFRs cause craniosynostosis (FGFR1-3)26–31 and
skeletal dysplasia (FGFR1 and 3),32–34 while loss-of-func-
tion mutations cause hypogonadotrophic hypogonadism
(FGFR1, [MIM 615465]) and Hartsfield syndrome (FGFR1,
[MIM 615465]).35,36 Lacrimoauriculodentodigital syn-
drome [MIM 149730] is caused by mutations in FGFR2,
FGFR3, and FGF10,37 and somatic activating mutations
in FGFR3 are present in some epidermal nevi.38 Both acti-
vating mutations and whole gene amplification of FGFR1
contribute to the pathogenesis of cancer.24,39 Although
activating mutations in the tyrosine kinase domain of
FGFR2 and FGFR3 have been reported,25 this is the first
report, to our knowledge, of activating mutations in
this domain in FGFR1 associated with a developmental
disorder.
Strikingly, the mutations identified in this study
in FGFR1 are paralogous to mutations in FGFR2 and
FGFR3 that cause craniosynostosis and skeletal dysplasia
(Figure 1F).17,25 The p.Lys650Glu substitution in FGFR3
causes thanatophoric dysplasia II (MIM 187601), and is pa-
ralogous to the ECCL-associated p.Lys656Glu substitution
in FGFR1.34 The p.Asn540Lys substitution in FGFR3, paral-
ogous to p.Asn546Lys in FGFR1, is the most common
cause of hypochondroplasia (MIM 1460000).40 Similarly,
paralogous substitutions of Asn549 and Lys659 in FGFR2
have been reported in individuals with syndromic cranio-
synostosis.41 The identification, in individuals with ECCL,
of amino acid substitutions in FGFR1 that are identical to
substitutions in other FGF receptors provides additional
support for the pathogenicity of these variants, and high-
lights the distinct roles FGFR1, 2, and 3 signaling during
human development.
The findings presented here highlight an emerging link
between recurrent somatic activating mutations in tumors
and mosaic developmental disorders that frequently have
an increased risk of cancer.42 ECCL represents the first
known example of a developmental disorder in the FGFR
family with an increased risk for cancer, specifically low-
grade gliomas.8–12 RTKs are one of the most commonly
mutated gene families in cancer and their contribution
to tumorigenesis is widely recognized.43 Not surprisingly,
both the c.1638C>A (p.Asn546Lys) and c.1966A>G
(p.Lys656Glu) mutations in FGFR1 are known oncogenic
mutations,44–47 and are the two most commonly mutated
residues among FGFR1mutation-containing tumors in the
COSMIC (Catalogue of Somatic Mutations in Cancer) data-584 The American Journal of Human Genetics 98, 579–587, March 3base.48 Interestingly, most of the tumors associated with
substitutions in these two residues are central nervous sys-
tem gliomas, including pilocytic astrocytomas,48,49 the
same type of tumor seen at increased frequency in individ-
uals with ECCL. In the pilocytic astrocytoma sample from
LR12-068, ES identified a second missense substitution,
p.Val561Met, also in the tyrosine kinase domain and in
cis with the p.Lys656Glu substitution. Previous studies
have shown that p.Val561Met confers a 38-fold increase
in phosphorylation of the FGFR1 receptor, as well as resis-
tance to lucitanib, an FGFR inhibitor currently in phase II
clinical trials for FGFR-dependent tumors.14,15 Whether
the p.Val561Met substitution actively contributes to
tumorigenesis remains to be elucidated. In individuals
with ECCL who develop low-grade gliomas, knowledge
of causative FGFR1mutations could lead to informed treat-
ment choices with targeted RTK inhibitors and improved
clinical management.
The RAS-MAPK pathway regulates crucial cellular
processes including DNA synthesis, cell growth, and dif-
ferentiation. Mutations in components of this pathway
cause a variety of developmental syndromes.50 Oculoecto-
dermal syndrome (OES; [MIM 600268]) is characterized
by congenital abnormalities of the scalp (cutis aplasia
and focal alopecia) and eyes (eyelid skin tags and epibul-
bar dermoids), features that are also seen in ECCL.51
OES has been proposed to be a milder form of ECCL,
which is distinguished from OES by the presence of CNS
lipomas.51 Notably, somatic mutations in KRAS have
recently been associated with OES.52 Considering the strik-
ing phenotypic overlap between ECCL and OES, hyperac-
tive RAS-MAPK signaling might represent a common
mechanism underlying these two disorders. The absence
of CNS lipomas in OES could be due to the relatively small
number of individuals with OES who have had brain imag-
ing, or could reflect the tissue distribution of these somatic
mutations. Specific differences in pathway activation due
to mutations in KRAS versus FGFR1 might also play a
role. Sequencing of KRAS in individuals with ECCL, and
FGFR1 in individuals with OES, will be helpful in address-
ing this question.
In summary, we identified two recurrent mutations
in FGFR1 in individuals with ECCL, a rare neurocuta-
neous disorder. We developed a smMIP assay to facilitate
screening of individuals with suspected ECCL and showed
that DNA derived from fibroblasts provides the highest
yield for identification of mutations in FGFR1. We identi-
fied a total of five FGFR1 individuals with FGFR1mutations
within our cohort of nine individuals for whom biopsy-
derived fibroblast DNA was available. We did not detect
any mutations among three individuals for whom only
blood- or saliva-derived DNA was available, but this does
not rule out the possibility of an FGFR1 mutation in other
tissues. Potential explanations for the individuals in the
cohort for whom an FGFR1 mutation was not detected
include (1) mutations present at a level below the limit
of detection of our smMIP assay, (2) underlying locus, 2016
heterogeneity, and (3) absence of available biopsy-derived
DNA for testing. With the exception of the brain tumor
from individual LR12-068, all of the samples that
possessed an FGFR1 mutation were from cultured fibro-
blasts, so that the mutation levels detected might reflect
selection for activating FGFR1 mutations in cell culture.
This might explain why the level of mutation in DNA
derived from individual LR12-068’s brain tumor (32%) is
lower than that of his scalp nevus (47%). Sequencing of
DNA from uncultured tissue samples from individuals
with ECCL will help address this issue. The phenotypes
of the individuals without detectable FGFR1 mutations
do not differ significantly from the individuals with
FGFR1 mutations (data not shown). Given the pheno-
typic similarities between OES and ECCL, screening these
individuals for KRAS mutations is a logical next step. Our
functional analysis of fibroblast cell lines harboring the
p.Asn546Lys substitution showed hyperphosphorylation
of FGFRs and downstream dependent substrates, consis-
tent with elevated activation of the receptor. Interestingly,
elevated FGFR1 signaling is implicated in both prolifera-
tion of humanmesenchymal stem cells and human preadi-
pocytes and might explain the striking nevus psiloliparus
seen in individuals with ECCL.53,54 We do not currently
understand how activating mutations in a single gene
can cause ECCL, craniosynostosis, and skeletal dysplasias.
It seems likely that the developmental timing and tissue
specific location of the post-zygotic FGFR1mutationmight
play an important role. Clearly different activating muta-
tions in FGFR1 can lead to distinct phenotypes, and further
studies are needed to understand the pleiotropic effects
of gain-of-function mutations in FGFR1. Finally this
work adds another gene to the growing number of disor-
ders due to mosaic mutations impacting the RAS-MAPK
pathway and further supports the emerging overlap be-
tween mosaic developmental disorders and tumorigenesis.Supplemental Data
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